Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
The European Commission ((EC)) has approved an additional indication for Astellas Pharma's (ALPMF) oral once-daily therapy Xtandi (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). The...
Astellas Pharma, Inc. (ALPMF) Q4 2021 Earnings Conference Call April 27, 2021 1:00 AM ET Company Participants Kenji Yasukawa - President & CEO Naoki Okamura - Corporate EVP, Chief Strategy Officer and CFO Yukio Matsui - Chief Commercial Officer Bernie Zeiher - Chief Medical Officer Confer...
The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Astellas Pharma Inc. 2020 Q4 - Results - Earnings Call Presentation
Astellas Pharma (ALPMF): FY Non-GAAP core basic EPS of ¥113.03; GAAP Diluted EPS of ¥64.90.Revenue of ¥1249.53B (-3.9% Y/Y)Press Release For further details see: Astellas Pharma reports FY results
Under Real-Time Oncology Review ((RTOR)) pilot program, FDA has accepted for review Seagen (SGEN) and Astellas Pharma's (ALPMF) two supplemental Biologics License Applications (sBLA) for PADCEV (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer.The applications...
Astellas Pharma (ALPMF) announces that a Phase 3 confirmatory trial of Xospata (gilteritinib) in patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia ((AML)) met its primary endpoint of overall survival ((OS)) compared to chemotherapy at a planned interim an...
Astellas Pharma ([[ALPMF]]) announced that the FDA has approved Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) for neurogenic detrusor overactivity (“NDO”) in children aged three years and older.The d...
The EMA has accepted Astellas Pharma (ALPMF) and Seagen's (SGEN) marketing authorization application ((MAA)) for enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor and a platinum-containing ...
Astellas Pharma ([[ALPMF]]) announced that its investigational oral, nonhormonal compound, fezolinetant yielded positive topline results in two Phase 3 trials evaluating its effect in moderate to severe vasomotor symptoms (“VMS”) – i.e., hot flashes associated with m...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...